CBG Faculty

W. Martin Kast

W. Martin Kast

Professor of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology;Walter A. Richter Cancer Research Chair;Director Medical Biology Graduate Program
Molecular Microbiology and Immunology
NRT 7507 1450 Biggy Street Health Sciences Campus Los Angeles

University of Southern California: Dornsife Award for Exceptional Service, 2019

Affymetrix: Affymetrix Prize, 2016

STOP Cancer: STOP Cancer Award, 2015

Rare Genomics Institute: BeHeard Ultimate Prize, 2015

University of Southern California: Mellon Award for Graduate Student Mentoring, 2014

University of Amsterdam: Landsteiner Prize, 2012

World Scientist Forum: North American Immunologist of the Year, 2010

IRPC: Eminent Scientist of the Year, 2010

Royal Netherlands Academy of Arts and Sciences: Royal Netherlands Academy of Arts & Sciences Award, 1991-1995

Netherlands Cancer Institute: Antoni van Leeuwenhoek Prize, 1991

Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors Gynecol Oncol. 2018 10; 151(1):102-110. . View in PubMed

Annexin A2 in Virus Infection Front Microbiol. 2018; 9:2954. . View in PubMed

Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation Sci Rep. 2018 08 03; 8(1):11642. . View in PubMed

Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy Oncotarget. 2017 Sep 26; 8(43):74378-74390. . View in PubMed

A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression Front Immunol. 2017; 8:563. . View in PubMed

Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection J Gen Virol. 2016 Feb; 97(2):422-434. . View in PubMed

Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro Virol J. 2016 11 18; 13(1):187. . View in PubMed

Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases Hum Vaccin Immunother. 2016 06 02; 12(6):1418-29. . View in PubMed

A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours J Gen Virol. 2015 Sep; 96(9):2764-2768. . View in PubMed

Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes Prostate. 2015 Feb 15; 75(3):280-91. . View in PubMed

Functional analysis of HPV-like particle-activated Langerhans cells in vitro Methods Mol Biol. 2015; 1249:333-50. . View in PubMed

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies J Transl Med. 2012 Nov 05; 10:218. . View in PubMed

Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability Int Rev Immunol. 2012 Oct; 31(5):302-20. . View in PubMed

Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy J Immunother. 2011 Jul-Aug; 34(6):490-9. . View in PubMed

Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer Int Rev Immunol. 2011 Apr-Jun; 30(2-3):127-37. . View in PubMed

Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors Vet Microbiol. 2010 Dec 15; 146(3-4):269-75. . View in PubMed

Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression Cancer Res. 2010 May 15; 70(10):3955-64. . View in PubMed

Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer PLoS One. 2010 May 12; 5(5):e10471. . View in PubMed

A major role for the minor capsid protein of human papillomavirus type 16 in immune escape J Immunol. 2009 Nov 15; 183(10):6151-6. . View in PubMed

Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, DC. Head Neck. 2009 Nov; 31(11):1393-422. . View in PubMed

Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer Gynecol Oncol. 2009 May; 113(2):256-63. . View in PubMed

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization Prostate. 2009 May 01; 69(6):571-84. . View in PubMed

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting Immunol Rev. 2008 Apr; 222:316-27. . View in PubMed

AKAP-4: a novel cancer testis antigen for multiple myeloma Br J Haematol. 2008 Feb; 140(4):465-8. . View in PubMed

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia Gynecol Oncol. 2007 Sep; 106(3):558-66. . View in PubMed

Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials Int Rev Immunol. 2007 May-Aug; 26(3-4):197-222. . View in PubMed

A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17 J Immunol Methods. 2007 Apr 10; 321(1-2):86-93. . View in PubMed

Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion Vaccine. 2006 Jun 12; 24(24):5235-44. . View in PubMed

Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors In Vitro Cell Dev Biol Anim. 2006 Mar-Apr; 42(3-4):89-95. . View in PubMed

Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells Vaccine. 2005 Feb 25; 23(14):1720-9. . View in PubMed

Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes Clin Cancer Res. 2004 May 15; 10(10):3301-8. . View in PubMed

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes Vaccine. 2004 Jan 02; 22(3-4):520-7. . View in PubMed

Cure of glioma: a space not yet occupied for the lesion Cancer Invest. 2004; 22(3):479-80. . View in PubMed

Advances in prophylactic cancer vaccine research Expert Rev Anticancer Ther. 2003 Aug; 3(4):537-45. . View in PubMed

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines Vaccine. 2003 Jul 04; 21(23):3219-27. . View in PubMed

Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells Cancer Res. 2003 Jul 01; 63(13):3478-82. . View in PubMed

Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation Vaccine. 2003 Jun 02; 21(19-20):2506-15. . View in PubMed

CD4+ T cell matters in tumor immunity Int Rev Immunol. 2003 Mar-Apr; 22(2):113-40. . View in PubMed

HPV protein/peptide vaccines: from animal models to clinical trials Front Biosci. 2003 Jan 01; 8:s81-91. . View in PubMed

Advances in immunotherapy for prostate cancer Adv Cancer Res. 2003; 87:159-94. . View in PubMed

Cervical cancer vaccines: recent advances in HPV research Viral Immunol. 2003; 16(2):111-21. . View in PubMed

Emerging strategies in tumor vaccines Curr Opin Oncol. 2002 Nov; 14(6):641-8. . View in PubMed

Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice Cancer Res. 2002 Oct 15; 62(20):5792-9. . View in PubMed

Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells Nat Med. 2002 Sep; 8(9):979-86. . View in PubMed

Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention Intervirology. 2002; 45(4-6):300-7. . View in PubMed

Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines Virology. 2001 Nov 25; 290(2):350-60. . View in PubMed

Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA Cancer Res. 2001 Nov 01; 61(21):7861-7. . View in PubMed

Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine J Immunol. 2001 May 01; 166(9):5366-73. . View in PubMed

A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy Clin Cancer Res. 2001 Mar; 7(3 Suppl):876s-881s. . View in PubMed

Cervical cancer vaccines: emerging concepts and developments J Cell Physiol. 2001 Feb; 186(2):169-82. . View in PubMed

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive Clin Cancer Res. 2000 Sep; 6(9):3406-16. . View in PubMed

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma J Immunother. 2000 Mar-Apr; 23(2):255-66. . View in PubMed

Effects of TGF-beta on the immune system: implications for cancer immunotherapy Leukemia. 1999 Aug; 13(8):1188-99. . View in PubMed

Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response J Cell Biochem. 1999 May 01; 73(2):145-52. . View in PubMed

Differential binding of viral peptides to HLA-A2 allelesImplications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol. 1999 04; 29(4):1292-303. . View in PubMed

Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the hepatitis B core antigen (HBcAg) c/e1-region Arch Virol. 1999; 144(7):1323-43. . View in PubMed

Active immunization against cancer cells: impediments and advances Semin Oncol. 1998 Dec; 25(6):697-706. . View in PubMed

Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC Cancer Res. 1998 Jul 15; 58(14):3094-100. . View in PubMed

Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells J Immunol. 1998 May 01; 160(9):4449-56. . View in PubMed

Cellular immunity and immunotherapy against deoxyribonucleic acid virus-induced tumors Monaldi Arch Chest Dis. 1998 Apr; 53(2):211-8. . View in PubMed

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model Proc Natl Acad Sci U S A. 1998 Feb 17; 95(4):1800-5. . View in PubMed

Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas Dev Biol Stand. 1998; 94:33-40. . View in PubMed

Activation or frustration of anti-tumor responses by T-cell-based immune modulation Semin Immunol. 1997 Oct; 9(5):323-7. . View in PubMed

HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS J Immunol. 1997 Oct 01; 159(7):3648-54. . View in PubMed

Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes Cancer Lett. 1997 Jun 03; 116(1):93-101. . View in PubMed

Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer Clin Cancer Res. 1996 Nov; 2(11):1825-8. . View in PubMed

Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts Int J Cancer. 1996 May 29; 66(5):686-91. . View in PubMed

Enhanced tumor outgrowth after peptide vaccinationFunctional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol. 1996 May 15; 156(10):3911-8. . View in PubMed

An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cellsIdentification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol. 1995 Dec; 44(4):189-98. . View in PubMed

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity Nat Med. 1995 Dec; 1(12):1297-302. . View in PubMed

Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors Eur J Immunol. 1995 Sep; 25(9):2638-42. . View in PubMed

Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor J Immunother Emphasis Tumor Immunol. 1995 Aug; 18(2):86-94. . View in PubMed

Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape Biochem Soc Trans. 1995 Aug; 23(3):692-6. . View in PubMed

Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization Immunol Lett. 1995 Jul-Aug; 47(1-2):1-8. . View in PubMed

Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells J Exp Med. 1995 Jul 01; 182(1):163-74. . View in PubMed

Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2 Cancer Res. 1995 Jun 15; 55(12):2627-34. . View in PubMed

A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs Hum Immunol. 1995 May; 43(1):13-8. . View in PubMed

Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay Hum Immunol. 1995 May; 43(1):1-12. . View in PubMed

CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells J Immunol. 1995 Apr 15; 154(8):3991-8. . View in PubMed

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene J Immunol. 1995 Apr 01; 154(7):3396-405. . View in PubMed

Functional and ultrastructural aspects of antigen processing by dendritic cells Adv Exp Med Biol. 1995; 378:227-31. . View in PubMed

Class I MHC-peptide interactions: structural requirements and functional implications Cancer Surv. 1995; 22:37-49. . View in PubMed

Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity Mol Immunol. 1994 Dec; 31(18):1391-401. . View in PubMed

Differential effect of transporter Tap 2 gene introduction into RMA-S cells on viral antigen processing Eur J Immunol. 1993 Dec; 23(12):3082-8. . View in PubMed

Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides J Immunother Emphasis Tumor Immunol. 1993 Aug; 14(2):121-6. . View in PubMed

A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation J Immunol Methods. 1992 Oct 19; 155(1):101-11. . View in PubMed

Cytotoxic T lymphocytes against the antigen-processing-defective RMA-S tumor cell line Eur J Immunol. 1992 Jun; 22(6):1639-42. . View in PubMed

Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms Semin Cancer Biol. 1991 Oct; 2(5):347-54. . View in PubMed

Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumours and peptide-MHC binding Int J Cancer Suppl. 1991; 6:90-4. . View in PubMed

Different requirements for the regulation of transplantation tolerance induction for allogeneic versus xenogeneic major histocompatibility complex antigens Hum Immunol. 1990 Nov; 29(3):220-8. . View in PubMed

Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro Cell. 1990 Aug 10; 62(3):563-7. . View in PubMed

Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells EMBO J. 1990 Aug; 9(8):2621-9. . View in PubMed

Efficacy of cytotoxic T lymphocytes against virus-induced tumors Cancer Cells. 1990 Apr; 2(4):116-20. . View in PubMed

Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes Cell. 1989 Nov 17; 59(4):603-14. . View in PubMed

Allograft tolerance induction in adult mice associated with functional deletion of specific CTL precursors Transplantation. 1989 Nov; 48(5):844-7. . View in PubMed

Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells J Immunol. 1988 May 01; 140(9):3186-93. . View in PubMed

Dendritic cells and antigen presentation in the regulation of cytotoxic T lymphocyte responses against viruses and transplantation antigens Ann N Y Acad Sci. 1988; 532:280-91. . View in PubMed

Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infectionProtection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations. J Exp Med. 1986 Sep 01; 164(3):723-38. . View in PubMed

Alternative splicing in the mouse H-2Kd gene is not necessary for the classical Kd antigen function Immunogenetics. 1986; 24(4):267-74. . View in PubMed

Abolition of specific immune response defect by immunization with dendritic cells Nature. 1985 Nov 7-13; 318(6041):59-62. . View in PubMed

W. Martin Kast, PhD is a Professor of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology at the Norris Comprehensive Cancer Center (NCCC) of the University of Southern California in Los Angeles, CA. He holds the Walter A. Richter Cancer Research Chair and is the co-director of the NCCC Tumor Micro-environment program, the Director of the USC Medical Biology Graduate Program, the Director of the Beckman Center for Immune Monitoring, the Director of the K-12 Cancer Education Program for underrepresented minorities and the Associate Dean of Academic Integrity. A native of the Netherlands, he earned his BS, MS, and PhD summa cum laude, from the University of Amsterdam in the Netherlands. He has and is serving on multiple Study Sections including the National Institute of Health and the Cancer Prevention and Research Institute of Texas. His research involves the design of therapeutic cancer vaccines directed against human papilloma virus (HPV) and prostate cancer. Several of his therapeutic HPV vaccines have or are currently been tried out in clinical trials. He studies how HPV enters cells and also studies the interaction of HPV with the human immune system to find out how HPV escapes immune detection and how to reverse that. He has published over 280 articles that have been quoted more than 24,000 times and lead to a publication h-index of 82. He is also the inventor on 18 patents. His research is supported by NIH grants. He is an associate editor for the Journal of Translational Medicine, Cancers and Papillomavirus research. He also served as the secretary/treasurer of the International Papillomavirus Society from 2012-2019 and serves on the advisory board of 6 biotechnology companies. In his free time he is a Scoutmaster and an actor.
Powered by SC CTSI